Form 8-K - Current report:
SEC Accession No. 0001213900-25-030048
Filing Date
2025-04-09
Accepted
2025-04-08 20:30:09
Documents
14
Period of Report
2025-04-02
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0237665-8k425_denali.htm   iXBRL 8-K 36036
  Complete submission text file 0001213900-25-030048.txt   265810

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE deca-20250402.xsd EX-101.SCH 4172
3 XBRL DEFINITION FILE deca-20250402_def.xml EX-101.DEF 27297
4 XBRL LABEL FILE deca-20250402_lab.xml EX-101.LAB 37878
5 XBRL PRESENTATION FILE deca-20250402_pre.xml EX-101.PRE 25917
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0237665-8k425_denali_htm.xml XML 7468
Mailing Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022
Business Address 437 MADISON AVENUE 27TH FLOOR NEW YORK NY 10022 6469785180
Denali Capital Acquisition Corp. (Filer) CIK: 0001913577 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41351 | Film No.: 25823357
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)